In addition, we demonstrated a link between SPARC and AKR1B10 and FABP5 genes, which could aid in better stratifying NAFLD patients and identifying those at risk of disease progression. This evidence concerns the gene AKR1B10 and metabolic dysfunction-associated steatotic liver disease.